Institut Straumann AG is the Swiss operating company of Straumann Holding AG (SIX: STMN), commonly known as the Straumann Group. It is headquartered in Basel, Switzerland, and traces its origin to a research institute founded in Waldenburg in 1954; the group has been listed on the SIX Swiss Exchange since 1998 and remains partly held by the founding Straumann family (~15–16%). It is a public operating company, not a holding shell: FY2025 revenue was CHF 2.6bn (FY2024: CHF 2.5bn) with close to 12,000 employees worldwide, and market capitalization was reported at roughly CHF 18bn at end-2024 (Straumann Group FY2024 annual report and full-year releases).
Products / operations. The group develops and manufactures dental implants and related hardware for tooth replacement and restoration, sold in more than 100 countries through subsidiaries and distributors. Its lines include premium implant systems (Straumann) and value/challenger implant brands (Neodent, Medentika, Anthogyr, T-Plus); implant prosthetics and precision instruments; biomaterials and oral-tissue regeneration products (e.g., Emdogain); clear-aligner orthodontics (ClearCorrect); and digital dentistry (intraoral scanners, CAD/CAM prosthetics via Dental Wings and etkon), plus clinician education. Its direct-to-consumer aligner business, DrSmile, was divested and reported in discontinued operations.
Patent-litigation posture. In the tracked data, Institut Straumann AG appears once and only as a defendant (0 plaintiff, 1 defendant) — consistent with an operating company defending competitor patent claims rather than an NPE asserting a portfolio. The sole case sits in the U.S. District Court for the Western District of Texas, Waco Division, a venue widely regarded as plaintiff-friendly.
Notable case. Align Technology, Inc. v. ClearCorrect Operating, LLC, ClearCorrect Holdings, Inc. & Institut Straumann AG, No. 6:24-cv-00187 (W.D. Tex., filed Apr. 11, 2024), pits Straumann's ClearCorrect aligner subsidiary (acquired in 2017 for ~USD 150m) against rival Align, which asserts nine patents covering multilayer aligner materials, treatment planning, and composite imaging. ClearCorrect and Straumann USA counterclaimed and filed IPR petitions (IPR2025-00816/-00820); Institut Straumann AG separately moved to dismiss for lack of personal jurisdiction, asserting it is distinct from ClearCorrect. The companies' earlier Align–ClearCorrect dispute settled in 2018 with a USD 35m payment by Straumann and a distribution agreement (media reports).